Member Info for B2HS2L

I tr ...

Did he get snatched away by a bored hungry hawk looking for lunch...

Or did he burst into tears reflecting on todays offerings, and pressed 'post message' while reaching for a kleenex?

Anyone got a number for Samaritans?

............|

............|

........../..\

......../__..\

........|.......|

........|.......|

........|...A..|

........|...V...|

........|...A..|

........|...C..|

........|...T...|

........|...A..|

........|.......|

........|.......|

........|.......|

........|.......|

......./|#||#|\

....../.|#||#|.\

...../..|#||#|..\

.....|../^||^\..|

.....|./.^||^.\.|

.....|/..^||^..\|

........(VVV)

.........(VV)

..........(V)

..........*l*

.........( * )

.....( % : % )

...( %%:%%)

..( % % % % )

.(..%%%%%.)

(£#£#£#£#£#£)

Episode 14 - 24.02.2026

This is how my transcript reads for the last slide. Adjust speed to 0.75 for clarity then:

16:50 CC: And the tumor can just keep using FAP over and over again. It cleaves and it can cleave again.

So in conclusion (Slide 11), lets pull this all together.

The conclusions from the tumor and plasma PK, very rapid tumor penetration, so the T-max there, we get that early spike in the tumor, the second is we get a much higher, (a log higher!) concentration in the tumor, so you get that initial hit of the drug.

Then finally we have nearly three times higher tumor selectivity of the preCISION delivery versus inHER2.

Then we think that these changes, these PK changes are translating, albeit some of them are subtle, but some subtle differences between the animal models.

So we get anti tumor activity, robust, durable, and reproducible anti tumor activity, even at that really low FAP expression which is what we need to see as we move into the clinic.

And then in terms of FAP overall, one of the nice things about this target FAP is it's stable,

because it's expressed on the fibroblast and not necessarily the tumor cells.

It's really not going away, - so even as we continue to dose our drugs, they're going to get cleaved, even if the tumor dies.

The fibroblast are still going to stick around, so that's the difference in the mechanism of action.

(Ruairidh: 'That's why we are so excited'. - Now look at frame 18:22, and the look on all three faces. CC struggling to remain deadpan.)

We get asked 'well what is the implication of this'.

I think it increases our likelihood of success, - the probability of success of AVA6103, - as it moves into the clinic and gets started in phase one.

++++

Have we been told all the R&D findings here?

Nope!

However, it's great news for those whose cancer has metastasized.

Aldebaran

I was thinking the reason Avacta has not sought Accelerated Approval for AVA6000 (yet), is because they do not want to

do anything that encourages an auction for AVCT (yet).

Then they generate an RNS like yesterdays, - a wakeup call to ADC developers.

Bella, moving on from ADC development may be a bitter pill for some BP to swallow financially, but is rapidly becoming necessary,

else a competitor grabs all the IP for the next tech wonder.

All BP can do is get their finances ready ASAP for that auction.

Aldebaran,

https://business-news-today.com/avacta-group-aim-avct-claims-precision-payload-delivery-shows-structural-advantages-over-adcs-as-ava6103-nears-clinic/

"Avacta Group plc is not positioning preCISION as an incremental ADC improvement. It is arguing that the entire delivery architecture can be simplified by removing the antibody component altogether and relying instead on tumor-specific protease activation within the tumor microenvironment. The preCISION platform uses fibroblast activation protein as the gating mechanism, a protease broadly upregulated across solid tumors and largely absent from healthy tissue.

This distinction matters strategically. ADC innovation has increasingly revolved around linker chemistry and payload potency, while the delivery vehicle itself has remained largely unchanged. Avacta Group plc is effectively questioning whether antibodies are the optimal delivery vehicle at all when tumor-activated small-molecule conjugates can achieve faster penetration and higher local exposure with lower systemic spillover."

+++

This article is calling time on ADC's per se.

Avacta's PDC does a more precise job with many fewer side effects, and is 1/10 the cost of an ADC to manufacture.

It's stating what other biopharma aren't stating, - that our IP is more robust for killing cancer cells.

I'm sure it hasn't escaped the attention of BP that all necessary IP is available.

One validation of note:

Alexander Spira MD, PhD, FACP, FASCO, Co-Director, Virginia Cancer Specialists (VCS) Research Institute; Director, VCS Thoracic and Phase 1 Program; Chief Scientific Officer, NEXT Oncology; and Clinical Assistant Professor, Johns Hopkins also commented:

"I am thrilled to work with Avacta on this exciting new drug.

The ability to concentrate a potent topoisomerase I inhibitor directly in the tumor while protecting normal tissues from harmful effects is the next stage of how we should be treating cancer.

We are looking forward to participating in this second pre|CISION® Phase 1 trial and helping the Company to drive this pioneering technology forward."

Another validation of note is within an RNS announcing FDA IND clearance:

"LONDON and PHILADELPHIA - January 21, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company's second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.

The IND approval is an important step in the development of AVA6103 as this is the point where the program moves from the lab into human testing."

+++

exatecan testing in humans in four indications and two schedules of administration

(every two weeks, Q2W and every three weeks, Q3W), sanctioned by FDA.

Preliminary data from this trial anticipated in the second half of 2026.

+++

External validation not the problem it was, but will become indisputable should AVA6103 phase 1 results be satisfactory.

Exatecan is around 4 to 5 times more powerful than deruxtecan, found in Enhertu.

exatecan delivered via 6103 will probably be better targeted but we await trial results.

Not really anything new as such

Avacta have used AI to reverse engineer AZN Enhertu results for comparison with 6103 results.

Wouldn't be surprised to see some adverse reactions from AstraZeneca/Daiichi Sankyo product because:

1 Avacta Analysis states AVA6103 PDC performance in AI assisted comparison with

2 AstraZeneca/Daiichi Sankyo ADC performance, - which is one of the most successful drugs on the market presently.

There is no benefit for an analyst to make those predictions.

They know any prediction is likely to be totally incorrect, and there is no + or - % allowance when predicting.

Particularly when no phase 1a data exists. - Not due until later 2026.

Indeed. That would be great news. 🤗

It would be wonderful if the same FDA team who constituted the pre-IND discussions FW referred to,

were the same team who made Accelerated Approval decisions.

A little more on Uniphar:

About Uniphar

Uniphar is a trusted global partner to pharma, medtech and biotech, delivering solutions that connect medicines and technologies with patients worldwide.

With over 57 years of experience and partnerships with 200+ multinational clients, Uniphar combines deep expertise, global infrastructure and market insight to meet the evolving needs of the life sciences sector.

Uniphar Pharma integrates Development, Clinical, Access, Medical, Commercial, Distribution and Global Sourcing to support the full product lifecycle - from early-stage research through to commercialisation and beyond.

Uniphar's unified platform spans regulatory strategy, medical affairs, market access, patient engagement, commercial services, distribution and supply chain.

Operating across 180 countries with a global team of 3,500+, Uniphar bridges manufacturers, healthcare providers, and patients - accelerating access to innovative therapies, improving patient outcomes, and delivering value across the healthcare ecosystem.

From molecule to market and beyond.

Thanks for the update Bella

FWIW - Source Grok :

Question - Are Healthcare Royalty and Uniphar connected in any way

Answer - Yes, Healthcare Royalty (also known as HealthCare Royalty Partners or HCRx) and Uniphar are connected through at least one individual.

David Bryant serves as a Senior Advisor to Healthcare Royalty, where he supports investments across the UK and Europe.

At the same time, he has joined Uniphar as a Board Advisor to their Pharma division.

This creates a personal/professional link via shared advisory expertise in the pharmaceutical and healthcare investment space.

David Bryant's background includes senior roles at companies like GSK, Pfizer, and Clinigen.

There is no evidence of a direct business partnership, investment, acquisition, or competitive overlap between the two companies themselves:

Healthcare Royalty is a U.S.-based firm (recently majority-acquired by KKR in 2025) specializing in biopharma royalty acquisitions and debt-like investments in commercial-stage assets.

Uniphar is an Ireland-based healthcare services company focused on pharma distribution, commercialization, logistics, and partnerships (e.g., recent distribution deals like with Santhera for AGAMREE in GCC countries).

No direct royalty deals, funding arrangements, or portfolio connections appear between them based on available information.

The connection is primarily through this shared advisor rather than a corporate relationship.

+++

Added value for Avacta now that NED David Bryant has improved his industry connections and possible utility.

It looks like he's becoming a key jigsaw piece.

Saint 68 - 'To further those discussions'

..IMO to maximise the possibility that attendee's having an interest in certain trials / projects / subjects / timescales get to know who else is having/due to have meetings with CEO/CFO/CSO.

Otherwise to keep radar on full update/titbit alert for later download with attendee's senior management.

10 Feb 2026 15:31

My request to Cohesion has not elicited a response, neither have they issued a receipt.

Has anyone sent a query to Cohesion and got a response please?

Stephen Harrison

https://www.linkedin.com/in/stephen-harrison-5b24911/

Michelle Morrow as CSO Nucleome Oxford.

https://nucleome.com/nucleome-therapeutics-appoints-experienced-biotech-executive-dr-michelle-morrow-as-chief-scientific-officer/

Cannot find more info on previous Nucleome CSO Dr Steven Harrison.

Also

From Linkedin - Overview

Nucleome was founded by leading experts in gene regulation from the University of Oxford. The Company is backed by a world-class syndicate of investors that includes M Ventures, the strategic corporate venture capital arm of Merck KGaA; Johnson and Johnson Innovation-JJDC, Inc. (“JJDC”), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Patient Capital; and founding investor Oxford Science Enterprises.

Nucleome was founded in 2019. The precision of its 3D genomics technology has the potential to improve drug discovery success rates both by discovering genetically-validated medicines, and by more accurately identifying patients who are likely to benefit from treatments. Nucleome’s platform can be applied to multiple disease indications and cell types, with an initial focus on inflammatory conditions. In addition to building its own pipeline, the company is forging external collaborations in target discovery, target validation, and patient stratification.

Haven't you got somewhere more profitable to spend your time and money, than trying to convert the unconvertable.

Wyndrone makes SO MUCH MONEY when invested elsewhere, - yet gets a new one ripped each time he tries to bore us all.

It must be to prove to himself he's an AVACTA victim.

You should be making the acquaintance of a Narcism specialist.

Just do it - sort your head out once and for all time, - for everyone's sake - you've told us you can afford it.

You know it makes sense.... or be forever victimised on AVACTA.

Slide 9

Discusses 6103 pre-IND discussions with FDA, and the very pro-active discussions that took place.

Making a video of such news would likely be a good way to 'spread the word' to potential partners that the FDA were very positive about Avacta's phase 1 proposals, and their handling of trials.

The FDA has also recently provided:

Allowance of flexibility in dosing levels

Removal of the dox lifetime limit in AVA6000.

The required 'Study May Proceed' letter.

The impression is that the trial was the best it could be before phase 1 starts.

It's great to know the IND ins & outs, but as feedback to negotiators on both sides, the video was worth the money spent making it.

Congratulations to our new CSO Francis Wilson, and the best of luck in his new endeavours.